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BackgroundandAims.Anarterialbloodsupplyandphenotypicchangesofthesinusoidscharacterisethelivervasculatureinhuman
hepatocellular carcinoma (HCC). We investigated the eﬀects of rosuvastatin on liver vessel anomalies, tumour growth and survival
in HCC. Methods. We treated transgenic mice developing HCC, characterized by vessel anomalies similar to those of human HCC,
with rosuvastatin. Results. In the rosuvastatin group, the survival time was longer (P<. 001), and liver weight (P<. 01) and
nodule surface (P<. 01) were reduced. Rosuvastatin decreased the number of smooth muscle actin-positive arteries (P<. 05) and
prevented the sinusoid anomalies, with decreased laminin expression (P<. 001), activated hepatic stellate cells (P<. 001), and
active Notch4 expression. Furthermore, rosuvastatin inhibited endothelial cell but not tumour hepatocyte functions. Conclusions.
Rosuvastatin reduced the vessel anomalies and tumour growth and prolonged survival in HCC. These results represent new
mechanisms of the eﬀects of statin on tumour angiogenesis and a potential target therapy in HCC.
1.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer in the world, with a poor prognosis. Vascular anoma-
lies are the main characteristics of large and moderately
or poorly diﬀerentiated HCC [1, 2]. Potential curative
treatments are only available in highly selected patients.
Sorafenib, an oral multikinase inhibitor targeting receptors
involved in angiogenesis and tumour growth, is the only sys-
temic treatment which has shown a modest, but signiﬁcant,
improvement in survival time in advanced HCC [3].
Among the various mechanisms involved in drug resis-
tance, mitochondrial cholesterol could mediate resistance to
chemotherapy in HCC [4]. Thus, statins, which inhibit 3-
hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase, resulting in the decrease of mevalonate and cholesterol
synthesis[5],couldbeinterestingtouseincombinationwith
conventional therapies in HCC. However, clinical trials using
statins in cardiovascular treatments have failed to provide
conclusive results regarding their anticancer eﬀects [6]. In
contrast, a recent study demonstrated that statin treatment
is associated with a signiﬁcant reduction in the risk of HCC2 Gastroenterology Research and Practice
in diabetic patients [7]. Thus, statins might have a beneﬁcial
eﬀect in HCC, likely in relation with their natural targeting
towards hepatocytes [8]. Pravastatin treatment, alone or
combined with chemoembolization, improves survival in
patients with advanced HCC [9, 10].
The eﬀects of statins on angiogenesis are disparate,
depending on the drug concentrations and experimental
conditions used [11–14]. Statins decrease the farnesylation
and geranylgeranylation of small GTPase proteins involved
in cellular survival, proliferation, and migration [15]. Ras
and Rho, small GTP-binding proteins, are the main tar-
gets of statins [16]. By preventing RhoA localisation to
the cell membrane, cerivastatin decreases endothelial cell
(ECs) migration and reduces angiogenesis in matrigel and
chorioallantoic membrane assays [17].
The concept described by Folkman four decades ago
depicting that tumour neovascularisation is needed for
tumour growth (the angiogenic switch) appears more com-
plex than thought [18]. Some tumours such as HCC do not
originate in avascular tissue [19, 20]. Severe anomalies of
the liver vessels characterise human HCC [1, 2]. In contrast
to the predominant portal venous blood supply and fenes-
trated sinusoids present in normal liver, an arterialisation is
observed in HCC, characterised by an intense arterial blood
supply with enlarged arteries and unpaired arteries, not
associated with a bile duct. Furthermore, in tumour nodules,
sinusoids are anarchic, fused, tortuous, and dilated. These
sinusoids acquire a basal membrane rich in laminin and
they are surrounded by activated hepatic stellate cells (HSCs)
featuring sinusoid capillarisation. Activated HSCs express
smooth muscle actin (SMA) and produce proangiogenic
factor [1, 21] while normal sinusoids are surrounded by
HSCs only expressing desmin [1, 2].
The aim of this study was to determine if statin,
by preventing liver vessel anomalies, might delay tumour
progression and prolong survival in HCC. For this purpose,
we used transgenic mice developing HCC in a multistep
angiogenic and tumour progression [22]. In this HCC
model,wehavepreviouslydescribedsimilarvesselanomalies
to those of human HCC [23, 24] and have shown that PlGF
blockade delays tumour growth and reduces arterialisation
and sinusoid capillarisation [25].
The VEGF, Notch, and ephrin families play a key role
in development of the vascular network and arterial/venous
diﬀerentiation of blood vessels during embryogenesis and in
the adult mouse [26, 27]. In the HCC model, Delta-like 4
ligand,theactiveformoftheNotch4receptor,andephrinB2,
expressed by sinusoidal endothelial cells (ECs), are gradually
upregulated during HCC progression and facilitate the liver
vessel anomalies [23].
Here, we have demonstrated a signiﬁcantly longer sur-
vival rate, with reduced tumour growth, in rosuvastatin-
treated HCC compared with untreated HCC mice. Rosuvas-
tatin reduced the process of arterialisation of the liver vas-
culature resulting in smaller arteries and prevented sinusoid
capillarisation, with a decrease in laminin and active Notch4
expression. Furthermore, the number of activated hepatite
stellate cells surrounding the sinusoids was reduced under
rosuvastatin treatment.
2.MaterialsandMethods
2.1. Reagents. The following antibodies were used for West-
ern blots and immunoﬂuorescence staining experiments:
A, rabbit antismooth muscle actin (SMA) and rabbit anti-
HIF-1α (Abcam, Cambridge, UK); rat antimouse CD31,
(Pharmingen Becton Dickinson, Le Pont de Claix, France);
rabbit anti-Notch4, recognizing the truncated intracellular
domainofint3/Notch4(Upstate,Euromedex,Mundolsheim,
FranceandAbcam,Cambridge,UK);goatanti-β-actin(C11)
(Santa Cruz Biotechnology, CA) and rabbit antilaminin (L-
9393) (Sigma, Saint Louis MI, USA); and rabbit antidesmin
(RB-9014) (Neomarker Inc. Fremont CA; USA). B,s e c -
ondary antibodies for Western blots: donkey anti-goat IgG-
peroxidase and donkey antirabbit IgG-peroxidase (Jackson
Immuno Research Laboratory, West Grove, PA, USA); C,
secondary antibodies for immunostaining: Alexa Fluor 488
and 555 goat antirabbit and Alexa Fluor 488 and 555 donkey
anti-rat (Interchim, Asni` eres, France).
2.2. Transgenic Mouse Model. Transgenic C57Bl6/ASV-B
male mice developing HCC, in a multistep angiogenic and
tumour progression from hyperplastic to the diﬀuse stage
of HCC, have been described elsewhere [22]. Brieﬂy, a
precise targeting of the SV40 T early region expression in
the liver of transgenic mice was achieved using 700 base
pair of the antithrombin regulatory sequences to control
oncogene expression. The development of hepatocarcinoma
was restricted to male mice which were backcrossed with
C57BL/6J mice. Mice were treated, or not (6 mice/group),
with rosuvastatin given orally, daily (25mg/kg), from the
fourth week until death, for the survival study. The choice
of rosuvastatin was determined by its hydrophilic properties,
with minimum hepatic metabolism by cytochrome P450
systems [8]. For haematoxylin and eosin (HE) staining,
immunoﬂuorescence stainings, and Western blot studies, 4
supplementary mice/group were killed, at the diﬀuse stage
(16 weeks) to obtain the liver samples. Animal procedures
were conducted under anaesthesia, in accordance with
French government policy (Services V´ et´ erinaires de la Sant´ e
et de la Production Animale, Minist` e r ed el ’ A g r i c u l t u r e ) .
2.3. Hepatocyte Isolation from HCC Livers and Cell Cultures.
Hepatocytes were isolated from untreated HCC livers. The
procedure was adapted according to Riccalton-Banks [28].
HCC mice (16 weeks) were anesthetised with Xylasine
20μg/g body weight (Bayer,Division sant´ e animale, Puteaux,
France) plus Ketamine 50μg/g body weight (Virbac, Carros,
France) to perform the laparotomy and to expose the portal
vein. The liver was perfused through the portal vein with
a canula (22G, Vygon, Ecouen, France) connected to a
peristaltic pump. The hepatic vein was split. The liver was
perfused (ﬂow rate 10ml/min) with 250ml perfusion buﬀer
(0.2M NaCl, 2.7mM KCl, 0.7mM Na2HPO4,1 0m MH e p e s
pH 7.65) at 37◦C, followed by 100ml perfusion buﬀer
supplemented with 6.5mM CaCl2 and 20μg/ml Liberase
(Roche Diagnostics GmbH, Penberg, Germany) at 37◦Ca t
a ﬂow rate of 5ml/min. After perfusions, the liver wasGastroenterology Research and Practice 3
carefully excised and rinsed two times with 20ml perfusion
buﬀer. The liver capsule was peeled oﬀ and the liver was
dissociated in 100ml M199-10% FCS at 37◦C, to dissociate
the cells. The crude cell suspension was ﬁltered through
a 60-p.m mesh nylon screen (SCRYNEL NY60HC, VWR,
Fontenay-sous-Bois,France)andsedimentedfor30minutes,
at room temperature. The pellet, containing the hepatocyte
fraction, was suspended in 100ml M199-10% FCS and was
washed four times (1000rpm for 5 minutes). Hepatocytes
(150000cells/cm2) were cultured in collagen-coated plates
(0.15mg/ml) (BD, Bedford, MA, USA) in DMEM-10% FCS
plus 4.5g/l glucose. After microscopic morphology evalua-
tion, cells appeared well-diﬀerentiated, with a hepatocyte-
likemorphology.Tumourhepatocyteswereexpanded,frozen
in 10% DMSO, and kept in liquid nitrogen. After thawing,
cells were further passaged and used for the experiments.
Human endothelial cells (HUVECs) were isolated from
the umbilical vein and cultured in EBM2-20% FCS plus
2ng/ml FGF-2 as described [23].
2.4. Cell Proliferation and Matrigel Assays. For cell prolif-
eration assays, HUVECs (15000cells/well), in EBM2-20%
FCS, and tumour hepatocytes (50000cells/well), in DMEM-
4.5g/l glucose-10% FCS, were seeded in 6-well culture
plates. After 72 hours, cells were cultivated with or without
rosuvastatin at 10μM, 25μM, and 100μM for HUVECs
and 100μM for hepatocytes. Cells were counted every 24
hours (Zeiss Axiovert 25, Carl Zeiss, Sartrouville, France).
Results were the mean ± SD of three experiments done in
quintuplicate.
For Matrigel assays, HUVECs (100000cells/well) were
seeded on Matrigel gel (BD Biosciences, Le Pont-de Claix,
France) in 12-well culture plates, in EBM2-20% FCS, in
the presence or in the absence of rosuvastatin (100μM).
Capillary-like structure formation was observed after 18
hours (Zeiss, Axio Observer Z.1). Images were obtained
using a digital camera (Baumer TXD14, Radeberg, Ger-
many). Three experiments were performed in duplicate. The
number of sprouts was quantiﬁed with Histolab software
(Microvision, Evry, France). Results were the mean ± SD of
three experiments performed in duplicate.
2.5. Invasion Assay. Tumour hepatocytes (75000cells/cham-
ber), in serum-free medium, were seeded in the insert
coated with matrigel (BD Biosciences), in the presence or
absence of rosuvastatin (100μM). The lower chamber was
ﬁlled with 750μl RPMI 1640 containing 10% FCS to induce
chemotaxis. After 24 hours, the nonmigrated cells present in
the upper chamber were gently scraped away, and adherent
cellspresenton thelowersurfaceoftheinsertwereﬁxed with
methanol, stained with 1% toluidine/1% borax solution, and
counted with Mercator software (Explora Nova, La Rochelle,
France). Results (number of invading cells) were the mean ±
SEM of three experiments performed in duplicate.
2.6. Rho Activation Assay. Tumour hepatocytes or HUVECs
were cultured for two days with or without rosuvastatin
(100μM). The cells were then lysed and activated RhoA was
measured by the G-Lisa kit, according to the manufacturer’s
instructions (Cytoskeleton Inc, Denver USA). Brieﬂy, the
active, GTP-bound RhoA, but not the inactive, GDP-bound
form, in the biological sample binds to the rothekin-coated
plate. Bound active RhoA is then detected by incubation
with a speciﬁc anti-Rho primary antibody, followed by
a secondary antibody conjugated to peroxidase. Results,
expressed in absorbance (490nm), are the mean ± SD of
three experiments performed in duplicate.
2.7. Protein Extraction and Western Blot. Protein extraction
from liver biopsies (100–200mg) was performed as previ-
ously described [23]. Protein concentrations were assessed
using the BCA protein reagent assay kit (Pierce, Rockford,
Ill, USA). Samples were boiled in 4X Laemmli buﬀer. Protein
samples were resolved by electrophoresis through 4% to
12% gradient SDS-PAGE precast gels (NuPage, Invitrogen,
CergyPontoise,France)underreducingconditionsinMOPS
buﬀer (NuPage, Invitrogen). After transfer, (iBlot Transfer
device, Invitrogen), membranes were incubated overnight at
4◦C with primary antibody against Notch4 (1/200), HIF-1α
(1/1000), and β-actin (1/400), used as an internal loading
control, then incubated with the appropriate secondary
antibody (1/50000). Antibody binding was revealed with the
ECL system (Pierce, Rockford, Il USA). The results (mean ±
SEM) were normalised to the β-actin levels and expressed as
a percentage of the control.
2.8. Immunoﬂuorescence (IF) Staining. Liver sections were
prepared as previously described [22]. The primary antibody
was omitted, or incubated with an excess of blocking peptide
as a negative control. Liver sections were incubated with
primary antibody: monoclonal rat anti-CD31 (1/50), anti-
laminin (1/100), anti-desmin (1/200), anti-Notch4 (1/100),
and anti-SMA (1/50) and then with the appropriate sec-
ondary antibody (1/200). All immunostainings were anal-
ysed using a standard ﬂuorescence microscope (Zeiss Axio
Observer Z1, Microvision, Evry, France).
Area staining and vessel quantiﬁcations were performed
using Histolab software (Microvision) by a blinded inves-
tigator. Nodular size was determined by area measurement
per optical ﬁeld (3 optical ﬁelds per liver). CD31, laminin,
desmin, and SMA sinusoidal expression were determined by
area measurement per optical ﬁeld (3-4 optical ﬁelds per
liver) and SMA vessel density was obtained by vessel counts
per section.
2.9. Statistical Analysis. The logrank test was performed
for the survival time. Data were analysed statistically using
the Student’s t-test (Excel; Microsoft), where P<. 05 was
considered signiﬁcant (
∗P <. 05; ∗∗P <. 01; ∗∗∗P <. 001).
3. Results
3.1. Rosuvastatin Prolongs Survival and Delays Tumour
Growth in HCC Mice. Rosuvastatin-treated HCC mice
showed a signiﬁcantly longer survival time than the
untreatedHCC mice.Themediansurvivaltime was195 days4 Gastroenterology Research and Practice
(range: 193–198) in the untreated mouse group and 216 days
(range: 214–220) in the rosuvastatin-treated HCC mouse
group (P<. 001) (Figure 1(a)).
At 16 weeks, a signiﬁcant increase in liver weight was
noted in untreated HCC mice (5.87 ± 0.34g) compared
with normal wild-type mice (N) (1.1 ± 0.05g) (P<. 001)
(Figure 1(b)). Rosuvastatin treatment signiﬁcantly decreased
the liver weight (4.18 ± 0.43g, P<. 01) (Figure 1(b))a n d
liver size (Figure 1(c)). Smaller nodules were present in HCC
livers under rosuvastatin treatment (Figure 1(c)).
We then analysed the liver architecture by HE staining.
At the diﬀuse stage of untreated HCC (16 weeks), large and
fused tumour nodules were present within the liver tissue
(Figure 1(d)). In contrast, at 16 weeks, smaller nodules were
present within the liver tissue under rosuvastatin treatment
(Figure 1(d)).Averagenodulesurfaceareasweresigniﬁcantly
reduced in rosuvastatin-treated HCC (0.13 ± 0.054mm2)
compared with untreated HCC livers (0.57 ± 0.15mm2;
P<. 01) (Figure 1(e)). Altogether, these results suggest that
rosuvastatin delays HCC progression.
3.2. Rosuvastatin Prevents Sinusoidal Anomalies in HCC
Livers. We analysed the sinusoids in normal livers and in
the nodular and internodular regions in untreated and
rosuvastatin-treated HCC livers (Figure 2(a)). As previously
described [22], a thin, regular sinusoidal network was
observed in normal livers, whilst fused, enlarged, and
tortuous sinusoids were present in untreated HCC livers.
These sinusoidal anomalies were more marked within the
nodular than within the internodular regions (Figure 2(a)).
The sinusoids were less extensively enlarged and chaotic in
the nodular and internodular regions in treated compared
with untreated HCC (Figure 2(a)).
We then carried out CD31 staining (Figure 2(b)). A
very faint expression of CD31 in sinusoidal ECs with a
regular sinusoidal network was present in normal livers
(Figure 2(b)). In contrast, a strong expression of CD31 was
observed in ECs lining the enlarged, tortuous, abnormal
sinusoids in untreated HCC livers (Figure 2(b)). Interest-
ingly, the sinusoids were less dilated and more regular,
with a weaker CD31 expression in sinusoidal ECs under
rosuvastatin treatment (Figure 2(b)).
Rosuvastatin signiﬁcantly reduced the sinusoid surface
areas. The CD31-positive areas were 10863 ± 1762μm2 in
untreated HCC livers versus 6589±738μm2 in rosuvastatin-
treated HCC (P<. 05) (Figure 2(c)).
3.3. Rosuvastatin Prevents Sinusoid Capillarisation in HCC
Livers. In normal livers, the sinusoids are fenestrated ves-
sels, without pericyte coverage, but surrounded by normal
hepatic stellate cells (HSCs) expressing desmin. In HCC,
the sinusoids develop into capillaries. They acquire a basal
membrane rich in laminin and are surrounded by activated
HSCs expressing SMA [1, 2, 25].
No laminin expression was depicted in normal livers
whilst laminin was markedly expressed in untreated HCC
livers (Figure 3(a)). In rosuvastatin-treated livers, a weaker
laminin staining was observed (Figure 3(a)). Furthermore,
the shape and size of the sinusoids were more regular
under rosuvastatin treatment, conﬁrming the HE and CD31
stainings (Figure 3(a)). We, then, compared the averaged
surface of laminin-positive sinusoids in untreated and
treated HCC livers. Rosuvastatin decreased laminin expres-
sion (laminin-positive areas: 2435 ± 562μm2/ ﬁ e l di nt r e a t e d
versus 9625 ± 1840μm2/ﬁeld in untreated HCC livers (P<
.001) (Figure 3(d)).
We, then, performed CD31/desmin and CD31/SMA
double-immunostainings, in order to analyse the HSCs
phenotype.
In normal livers, desmin stained mural cells in ves-
sels derived from the portal tract and nonactivated HSCs
(Figure 3(b), see Figure 1(a) in Supplementary Material
available online at doi: 10.1155/2010/640797.), while SMA
stained only arteries (Figure 3(c), Supplementary Figure
1(b)).Thedesmin-positiveareaswerehigherinrosuvastatin-
treated (13921 ± 1956μm2/ﬁeld) than those in untreated
HCC livers (4020±1374μm2/ﬁeld, P<. 05) (Figure 3(e)). In
normal livers, desmin-stained mural cells in vessels derived
from the portal tract and SMA-stained smooth muscle cells
inarteries(SupplementaryFigures 1(a),1(b).CD31-positive
sinusoidal ECs were surrounded by non-activated HSCs
expressing desmin in normal, untreated and rosuvastatin-
treated HCC livers ((Supplementary Figure 1(a)) whilst they
were surrounded by activated HSCs expressing SMA only
in HCC livers (Supplementary Figure 1(b)). Interestingly,
in rosuvastatin-treated HCC livers, CD31-positive sinusoidal
ECs were more intensely surrounded by non-activated
desmin-positive HSCs than in untreated HCC livers (Sup-
plementary Figure 1(a)).
In normal livers, SMA stained smooth muscle cells
in arteries (Figure 3(c)). Rosuvastatin markedly decreased
the SMA-positive-activated HSCs compared with untreated
HCC (Figures 3(c) and 3(f)). The average surface area
of SMA-positive HSCs was 688 ± 147μm2/ ﬁ e l di nt r e a t e d
versus 5180 ± 389μm2/ﬁeld in untreated HCC livers (P<
.001) (Figure 3(f)). In treated HCC livers, CD31-positive
sinusoidal ECs were less intensely surrounded by SMA-
positive-activated HSCs than those in untreated HCC livers
(Supplementary Figure 1(b)). Altogether, these data sug-
gestedthatrosuvastatinimpairs HSCactivationandprevents
sinusoid capillarisation in HCC.
3.4. Rosuvastatin Prevents Arterialisation in HCC Livers. In
healthy livers, the portal vein supplies the majority of hepatic
blood ﬂow. In contrast, HCC is characterised by an increase
in the liver arterial blood supply, leading to an increase in the
number of arteries [1, 2, 25].
We observed that rosuvastatin reduced the number of
SMA-positive arteries in HCC compared with untreated
HCC livers (12 ± 5.5/mm2/section for treated HCC versus
23.7±4.3/mm2/sectionforuntreatedHCC,P<. 05)(Figures
4(a) and 4(b)).
3.5. Rosuvastatin Reduces the Expression of Active Notch4 in
Sinusoidal Endothelial Cells in HCC. We have previously
reportedthattumoursinusoidalECschangetheirphenotypeGastroenterology Research and Practice 5
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treated HCC livers (n = 4/group) at 16 weeks. Data are expressed as mean ± SEM (
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Figure 2: Rosuvastatin prevents sinusoid abnormalisation in HCC livers. (a) Representative images of haematoxylin-eosin (HE) staining in
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Figure 3: Rosuvastatin prevents sinusoid capillarisation in HCC livers. (a) Representative images of laminin immunostaining in normal
livers (N, n = 4), untreated HCC, and rosuvastatin-treated HCC livers (n = 4/group) at 16 weeks. Laminin was expressed by the sinusoids
(white arrowhead) only in HCC livers. A weaker expression of laminin was observed in treated-HCC livers compared with untreated HCC.
(b) Representative images of desmin immunostaining in normal livers (N, n = 4), in untreated HCC, and in rosuvastatin-treated HCC livers
(n = 4/group) at 16 weeks. Desmin was expressed in mural cells lining vessels derived from the portal tract (VDPT) in normal livers (white
arrow). Desmin was expressed in nonactivated hepatic stellate cells (HSCs) surrounding the sinusoids in both livers (white arrowhead). (c)
Representative images of SMA immunostaining in normal livers (N, n = 4), in untreated HCC, and in rosuvastatin-treated HCC livers
(n = 4/group) at 16 weeks. SMA was expressed by smooth muscle cells lining arteries (white arrow). SMA was expressed in activated HSCs
surrounding the sinusoids in HCC livers (white arrowhead). (d) Quantiﬁcation of laminin-positive sinusoid surface per ﬁeld, in untreated
HCC and in rosuvastatin-treated HCC livers (n = 4: group) at 16 weeks. Data are mean ± SEM,
∗∗∗P <. 001. (e) Quantiﬁcation of desmin-
positive hepatic stellate cell (HSC) surface area per ﬁeld in untreated HCC and in rosuvastatin-treated HCC livers (n = 4/group). Data are
mean ± SEM,
∗∗P <. 01. (f) Quantiﬁcation of SMA-positive HSC surface area per ﬁeld in untreated HCC and in rosuvastatin-treated livers
(n = 4/group). Data are mean ± SEM,
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Figure 4: Rosuvastatin prevents arterialisation in HCC livers. (a) Representative images of SMA immunostaining in arteries in normal livers
(N, n = 4), in untreated HCC and in rosuvastatin-treated HCC livers (n = 4/group) at 16 weeks. SMA stained smooth muscle cells lining
arteries (white arrow). (b) Quantiﬁcation of SMA-positive arteries per section in untreated HCC, and in rosuvastatin-treated livers (n = 4:
group). Data are mean ± SEM,
∗P <. 05.
and express the active form of Notch4, an arterial EC marker
[23]. As previously reported, Notch4 was expressed by
sinusoidal ECs in HCC livers (Figure 5(a)). Fewer sinusoids
expressed Notch4 in treated compared with untreated HCC
livers (Figure 5(b)). By western blot, we demonstrated that
rosuvastatin signiﬁcantly reduced the levels of active Notch4
by 71% (P<. 001) in HCC livers (Figure 5(c)).
3.6. Rosuvastatin Reduces the Expression of HIF-1α in HCC
Livers. We previously described that the HIF-1α messenger
was increased in HCC livers [22]. Here, we showed, by
western blot, that HIF-1α levels increased to 336 ± 7%
i nH C Cl i v e r sc o m p a r e dw i t hn o r m a ll i v e r s( Figure 6).
Compared with untreated HCC, rosuvastatin signiﬁcantly
decreasedHIF-1αlevelsto284±19%(P<. 01)inHCClivers
(Figure 6).
3.7. Rosuvastatin Has No Eﬀe c to nT u m o u rH e p a t o c y t e
Proliferation, Invasion, and Rho Activity. We ﬁrst analysed if
the delay in HCC progression was related to the eﬀects of
rosuvastatin on tumour hepatocytes. The numbers of Ki67
positive-cells/ﬁelddidnotdiﬀersigniﬁcantlybetweentreated
(119 ± 59) and untreated HCC livers (140 ± 38) and were
signiﬁcantly higher than those of normal livers (4 ± 0.8,
P<. 001) (Figures 7(a) and 7(b)).
Rosuvastatin (100μM) had no in vitro eﬀect on tumour
hepatocyte proliferation and invasion (Figures 7(c) and
7(d)).
AsRhoisatargetofstatins,westudiedtheinvitroactiva-
tion of Rho in cultured tumour hepatocytes under rosuvas-
tatin treatment. Rosuvastatin (100μM) did not modify the
activation of Rho in tumour hepatocytes (Figure 7(e)).
Thus, our results suggest that Rosuvastatin does not act
directly on tumour hepatocytes.
3.8. Rosuvastatin Inhibits Proliferation, Diﬀerentiation, and
Rho Activation of HUVECs. We, then, analysed the in
vitro eﬀects of rosuvavastatin on HUVECs. The inhibition
of HUVEC proliferation by rosuvastatin (10–100μM) was
dose- and time-dependent (Figure 8(a)). After 24 hours,
rosuvastatin inhibited HUVEC proliferation by approxi-
mately 25% for all concentrations. A dose-dependent eﬀect
of rosuvastatin was observed after 48 and 72 hours. After 48
hours, rosuvastatin signiﬁcantly inhibited HUVEC prolifer-
ation by 49% (P<. 001), 64% (P<. 001), and 78% (P<
.001) for 10, 25, and 100μM, respectively. After 72 hours, the
inhibitionreached66%(P<. 001),76%(P<. 001),and95%
(P<. 001) for 10, 25, and 100μM, respectively (Figure 8(a)).
In the absence of rosuvastatin, HUVECs diﬀerentiated
into capillary-like structures with highly branched sproutingGastroenterology Research and Practice 9
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Figure 5: Rosuvastatin reduces the expression of active Notch4 in sinusoidal endothelial cells. (a) Representative images of CD31/Notch4
double immunostaining in untreated HCC livers at 16 weeks. We showed that Notch4 was expressed by CD31-positive endothelial cells
lining the sinusoids (white arrowhead). (b) Representative images of Notch4 immunostaining in normal livers (N, n = 4), untreated HCC,
and in rosuvastatin-treated HCC livers (n = 4/group) at 16 weeks (white arrowhead). (c) Western blot analysis of active Notch4 in untreated
HCC and in rosuvastatin-treated HCC livers (n = 4/group) at 16 weeks. The results were normalised to the β-actin levels and expressed as a
percentage of Notch4 levels in untreated livers. Rosuvastatin decreased signiﬁcantly the levels of active Notch4 in HCC livers. Data are mean
± SEM,
∗∗∗P <. 001.
networks in Matrigel (Figure 8(b)). In the presence of
rosuvastatin, HUVECS formed sprouts, and the numbers
of sprouts did not diﬀer signiﬁcantly between untreated
and rosuvastatin-treated HUVECs (Figure 8(c)). Under
rosuvastatin treatment, HUVECs diﬀerentiated into cords
without lumen rather than capillary-like structures (Figure
8(b)).
Similar results were obtained for proliferation and tube
formation in Matrigel with human microvascular ECs (data
not shown).
We then analysed the eﬀect of rosuvastatin on Rho acti-
vationinHUVECS.RosuvastatininhibitedRhoactivationby
81% (P<. 001) at 25μM and by 86% (P<. 001) at 100μM
(Figure 8(d)).10 Gastroenterology Research and Practice
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Figure 6: Rosuvastatin decreases HIF-1α levels in HCC livers. Representative image of western blot analysis of HIF-1α in normal livers (N),
untreated HCC (n = 4), and in rosuvastatin-treated HCC livers (n = 4) at 16 weeks. The results were normalised to the β-actin levels
and expressed as a percentage of HIF-1α levels in normal livers. Data are mean ± SEM. HIF-1α was signiﬁcantly increased in HCC livers
compared with normal livers,
∗∗∗P <. 001. Rosuvastatin decreased signiﬁcantly HIF-1α levels in HCC livers,
∗∗P <. 01.
4. Discussion
Hypervascularity in human HCC is characterised by severe
anomalies of the liver vasculature with an increased arterial
blood supply, deﬁned as arterialisation, and phenotypic
modiﬁcations of the sinusoids, deﬁned as capillarisation
[1, 2]. In transgenic mice developing HCC in a multistep
angiogenic and tumour progression [22], we have reported
similar vessel anomalies to those in human HCC [23–25].
Thus, this model is appropriate to analyse the eﬀects of rosu-
vastatin on liver vessel anomalies and tumour progression in
HCC.Assorafenibistheonlyapprovedtherapyforadvanced
HCC [3], we decided to analyse the eﬀects of rosuvastatin at
the diﬀuse stage (16 weeks) of HCC in this transgenic HCC
model.
Here, we have shown that rosuvastatin, in vivo, signif-
icantly reduces tumour growth, as scored by liver weight
and nodule size, and signiﬁcantly prolongs survival in trans-
genic mice developing HCC. HCC progression, resistance
to chemotherapy, and intrahepatic recurrence have been
reported to be modulated by Rho GTPase signals, the main
targets of statins [29, 30]. In other rodent HCC models,
statin reduced tumour progression, lung metastasis, and
microvascular density. However, the eﬀect of statins on
survival was not established [31, 32]. The beneﬁcial eﬀect
of statins in HCC may be related to their natural targeting
towards hepatocytes [8]. Intriguingly, the number of pro-
liferative hepatocytes did not diﬀer between untreated and
rosuvastatin-treated HCC livers. Furthermore, rosuvastatin
did not inhibit, in vitro, the proliferation and invasion
of tumour hepatocytes isolated from HCC livers and the
activation of Rho in these hepatocytes.
We, thus, focused on the in vivo eﬀects of rosuvastatin
on liver vasculature in HCC. In contrast to the predominant
portal venous blood supply and the highly fenestrated
sinusoids in normal livers, an intense arterial blood supply
with an increase in unpaired arteries and a capillarisation of
the sinusoid vessels characterises the HCC vascular network
[1, 2]. We have previously shown, by ultrasonic mea-
surements and microarteriographic studies, a predominant
arterial blood supply with arterial-venous shunts in our
model of HCC [24]. Furthermore, we also showed in this
model that tumour sinusoids express laminin and that
tumour sinusoidal ECs acquire an arterial phenotype [22,
23]. These similarities between the liver vascular network in
human HCC and in our model prompted us to investigate
whether rosuvastatin may counteract liver vessel anomalies
in HCC.
Here, we have shown that rosuvastatin signiﬁcantly
reduces the number of SMA-positive arteries, suggesting that
rosuvastatin prevents arterialisation in our model of HCC.
We also demonstrated that rosuvastatin counteracts the
phenotypic changes of the sinusoids. Indeed, the sinusoids
were less anarchic, tortuous, and dilated and had partially
lost their basal membrane rich in laminin in rosuvastatin-
treated HCC. Normal sinusoids, lacking pericytes, are sur-
rounded by desmin-positive HSCs, while activated SMA-
positive HSCs are present in HCC [1]. Similar anomalies
were present in our HCC model. Indeed, desmin-positive
HSCs were decreased, whilst activated SMA-positive HSCs
were increased, in HCC compared with normal livers.
Interestingly, rosuvastatin increased the number of nonac-
tivated desmin-positive HSCs and decreased the number of
activated SMA-positive HSCs in HCC.
Notch signalling regulates cell proliferation and diﬀeren-
tiation and deregulated expression of Notch are described in
HCC [33]. Overexpression of Notch1 inhibits the growth of
HCC cells [34]. In contrast, downregulation of Notch1 sig-
nalling results in HCC cell growth inhibition and apoptosis
[35].
Arterial-venous endothelial cell fate is regulated by the
VEGF and Notch families [26, 36]. We have previously
reported that the VEGF-A/Dll4/active Notch4/ephrine B2
cascade promotes liver vessel anomalies in HCC and that
Notch4 is only expressed in tumour sinusoidal ECs [23].
Constitutive activation of Notch4 induces arteriovenousGastroenterology Research and Practice 11
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Figure 7: Eﬀects of rosuvastatin on tumour hepatocyte functions. (a) Representative images of Ki67 immunostaining in normal livers (N,
n = 4), untreated HCC, and in rosuvastatin-treated HCC livers (n = 4/group) at 16 weeks. (b) Quantiﬁcation of Ki67-positive hepatocytes.
Rosuvastatin did not aﬀect the number of Ki67-proliferative hepatocytes in HCC. (c) Proliferation of cultured hepatocytes isolated from
HCC livers with or without Rosuvastatin (100μM). Results, expressed as number of hepatocytes per well, are the mean ± S.D of three
experiments performed in quintuplicate. (d) Tumour hepatocyte invasion with and without rosuvastatin treatment (100μM). Adherent
tumour hepatocytes on the lower surface of the insert were counted with Mercator software. Results, expressed as a percentage of nontreated
tumour hepatocytes, are the mean ± SD of three experiments performed in duplicate. (e) Rho activation assays in tumour hepatocytes
with and without rosuvastatin treatment (100μM). Results, expressed as absorbance, are the mean ± SD of three experiments performed in
duplicate,
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malformations in adult mice, notably in the liver [37].
Notch4 signalling promotes lung and brain arteriovenous
malformations in mice [38, 39]. Since Notch4 signalling
induces vessel anomalies, we analysed the liver expression of
active Notch4 rather than Notch1 under rosuvastatin treat-
ment. Here, we showed that rosuvastatin reduced the levels
of the active form of Notch4, with fewer Notch4-positive
sinusoids. Such a decrease in active Notch4 expression
contributed, in part, to the beneﬁcial eﬀect of rosuvastatin
on liver vessel anomalies in the HCC model.
EvenifhypervascularityisahallmarkofHCC,livervessel
anomalies lead to impaired functional perfusion of HCC
livers and facilitate hypoxia [1, 25]. Hypoxia induces the
synthesis of angiogenic cytokines and stimulates HCC cell
growth and resistance to therapy [40]. Moreover, activated
HSCs secrete angiogenic factors and impair oxygen delivery
[1, 41, 42]. In favour of this hypothesis, we have previously
demonstrated an increase in HIF-1α messenger levels in the
HCC model [22]. Here, we showed an increase in HIF-
1α protein levels in untreated HCC compared with normal
livers. Interestingly, we showed that HIF-1α was impaired
under rosuvastatin treatment. Blockade of this cycle may
improve functional liver vascularisation and the eﬃciency of
therapies in HCC.
To our knowledge, these eﬀects of statins on the preven-
tion of arterialisation and sinusoid capillarisation in HCC
have not been previously reported.
Statins may promote or inhibit EC angiogenesis in
vitro [11–14]. Here, we showed that rosuvastatin inhibits
HUVECs proliferation, disorganizes the capillary network,
but not the sprout number, in Matrigel, and decreases the
activation of Rho.
Taken together, our data show that rosuvastatin prevents
the capillarisation of sinusoids and the arterialisation of the
liver vasculature, which may lead to reduced tumour growth
and longer survival in HCC. Rosuvastatin inhibited ECs
but not tumour hepatocyte functions, which might suggest
that rosuvastatin targets endothelial cells rather than tumour
hepatocytes. These results represent a new mechanism of the
eﬀects of statins on liver vessel normalisation in HCC and
suggest a potential target to optimise therapies in advanced
HCC.
Acknowledgments
This study was supported, in part, by a grant of the
L i g u eN a t i o n a l eC o n t r el eC a n c e r .T h ea u t h o r sa c k n o w l e d g e
Dr. R. Porcher for the statistical analyses, the Lariboisi` ere
Hospital Maternity Department for the umbilical cords sup-
plied, and Yves Millet for animal care. A. Tijeras-Raballand,
P. Hainaud-Hakim, and J.-O. Contreres contributed equally
to this work.
References
[1] M. Fern´ andez, D. Semela, J. Bruix, I. Colle, M. Pinzani, and
J. Bosch, “Angiogenesis in liver disease,” Journal of Hepatology,
vol. 50, no. 3, pp. 604–620, 2009.
[2] D. Ribatti, A. Vacca, B. Nico, D. Sansonno, and F. Dammacco,
“Angiogenesis and anti-angiogenesis in hepatocellular carci-
noma,” Cancer Treatment Reviews, vol. 32, no. 6, pp. 437–444,
2006.
[3] J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in
advanced hepatocellular carcinoma,” New England Journal of
Medicine, vol. 359, no. 4, pp. 378–390, 2008.
[4] J. Montero, A. Morales, L. Llacuna et al., “Mitochondrial
cholesterol contributes to chemotherapy resistance in hepato-
cellularcarcinoma,”CancerResearch,vol.68,no.13,pp.5246–
5256, 2008.
[5] M.JakobisiakandJ.Golab,“Statinscanmodulateeﬀectiveness
of antitumor therapeutic modalities,” Medicinal Research
Reviews, vol. 30, no. 1, pp. 102–135, 2010.
[6] J. Kuoppala, A. Lamminp¨ a¨ a, and E. Pukkala, “Statins and
cancer: a systematic review and meta-analysis,” European
Journal of Cancer, vol. 44, no. 15, pp. 2122–2132, 2008.
[7] H.B .El-Serag,M.L.J ohnson,C.H achem,andR.O .M organa,
“Statins are associated with a reduced risk of hepatocellular
carcinoma in a large cohort of patients with diabetes,”
Gastroenterology, vol. 136, no. 5, pp. 1601–1608, 2009.
[8] C. K. Argo, P. Loria, S. H. Caldwell, and A. Lonardo, “Statins
in liver disease: a molehill, an iceberg, or neither?” Hepatology,
vol. 48, no. 2, pp. 662–669, 2008.
[9] S. Kawata, E. Yamasaki, T. Nagase et al., “Eﬀect of pravas-
tatin on survival in patients with advanced hepatocellular
carcinoma. A randomized controlled trial,” British Journal of
Cancer, vol. 84, no. 7, pp. 886–891, 2001.
[10] H. Graf, C. J¨ u n g s t ,G .S t r a u be ta l . ,“ C h e m o e m b o l i z a t i o n
combined with pravastatin improves survival in patients with
hepatocellular carcinoma,” Digestion, vol. 78, no. 1, pp. 34–38,
2008.
[11] J. Dulak and A. J´ ozkowicz, “Anti-angiogenic and anti-
inﬂammatory eﬀects of statins: relevance to anti-cancer
therapy,” Current Cancer Drug Targets, vol. 5, no. 8, pp. 579–
594, 2005.
[12] C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler,
“Double-edged role of statins in angiogenesis signaling,”
Circulation Research, vol. 90, no. 6, pp. 737–744, 2002.
[13] M. Weis, C. Heeschen, A. J. Glassford, and J. P. Cooke, “Statins
have biphasic eﬀects on angiogenesis,” Circulation, vol. 105,
no. 6, pp. 739–745, 2002.
[14] X. Y. Zhu, E. Daghini, A. R. Chade et al., “Disparate
eﬀects of simvastatin on angiogenesis during hypoxia and
inﬂammation,” Life Sciences, vol. 83, no. 23-24, pp. 801–809,
2008.
[ 1 5 ] M .F .D e m i e r r e ,P .D .R .H i g g i n s ,S .B .G r u b e r ,E .H a w k ,a n dS .
M. Lippman, “Statins and cancer prevention,” Nature Reviews
Cancer, vol. 5, no. 12, pp. 930–942, 2005.
[16] M. R. Graaf, D. J. Richel, C. J. F. van Noorden, and
H. J. Guchelaar, “Eﬀects of statins and farnesyltransferase
inhibitors on the development and progression of cancer,”
Cancer Treatment Reviews, vol. 30, no. 7, pp. 609–641, 2004.
[17] L. Vincent, C. Soria, F. Mirshahi et al., “Cerivastatin, an
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase, inhibits endothelial cell proliferation induced by angio-
genic factors in vitro and angiogenesis in in vivo models,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no.
4, pp. 623–629, 2002.
[18] G. Bergers and L. E. Benjamin, “Tumorigenesis and the
angiogenic switch,” Nature Reviews Cancer,v o l .3 ,n o .6 ,p p .
401–410, 2003.14 Gastroenterology Research and Practice
[19] R. K. Jain, “Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy,” Science, vol. 307, no. 5706,
pp. 58–62, 2005.
[20] D. M. McDonald and P. Baluk, “Imaging of angiogenesis in
inﬂamed airways and tumors: newly formed blood vessels
are not alike and may be wildly abnormal: Parker B. Francis
lecture,” Chest, vol. 128, no. 6, pp. 602S–108S, 2005.
[21] BO. Xu, U. Broome, M. Uzunel et al., “Capillarization of hep-
atic sinusoid by liver endothelial cell-reactive autoantibodies
in patients with cirrhosis and chronic hepatitis,” American
Journal of Pathology, vol. 163, no. 4, pp. 1275–1289, 2003.
[22] E. Dupuy, P. Hainaud, A. Villemain et al., “Tumoral angio-
genesis and tissue factor expression during hepatocellular
carcinoma progression in a transgenic mouse model,” Journal
of Hepatology, vol. 38, no. 6, pp. 793–802, 2003.
[23] P. Hainaud, J. O. Contrer` es, A. Villemain et al., “The
role of the vascular endothelial growth factor-Delta-like 4
ligand/Notch4-Ephrin B2 cascade in tumor vessel remodeling
and endothelial cell functions,” Cancer Research, vol. 66, no.
17, pp. 8501–8510, 2006.
[24] P. Bonnin, A. Villemain, F. Vincent et al., “Ultrasonic
assessment of hepatic blood ﬂow as a marker of mouse
hepatocarcinoma,” Ultrasound in Medicine and Biology, vol.
33, no. 4, pp. 561–570, 2007.
[25] S. Van de Veire, I. Stalmans, F. Heindryckx et al., “Further
pharmacological and genetic evidence for the eﬃcacy of PlGF
inhibition in cancer and eye disease,” Cell, vol. 141, no. 1, pp.
178–190, 2010.
[26] J. Rossant and M. Hirashima, “Vascular development and
patterning: making the right choices,” Current Opinion in
Genetics and Development, vol. 13, no. 4, pp. 408–412, 2003.
[27] T. Kume, “Novel insights into the diﬀerential functions of
Notch ligands in vascular formation,” Journal of Angiogenesis
Research, vol. 1, p. 8, 2009.
[28] L. Riccalton-Banks, R. Bhandari, J. Fry, and K. M. Shakesheﬀ,
“A simple method for the simultaneous isolation of stellate
cells and hepatocytes from rat liver tissue,” Molecular and
Cellular Biochemistry, vol. 248, no. 1-2, pp. 97–102, 2003.
[29] K. Fukui, S. Tamura, A. Wada et al., “Expression and prognos-
ticroleofRhoAGTPasesinhepatocellularcarcinoma,”Journal
of Cancer Research and Clinical Oncology, vol. 132, no. 10, pp.
627–633, 2006.
[30] P. Sterpetti, L. Marucci, C. Candelaresi et al., “Cell pro-
liferation and drug resistance in hepatocellular carcinoma
are modulated by Rho GTPase signals,” American Journal of
Physiology, vol. 290, no. 4, pp. G624–G632, 2006.
[31] D. Taras, J. F. Blanc, A. Rullier et al., “Pravastatin reduces lung
metastasis of rat hepatocellular carcinoma via a coordinated
decrease of MMP expression and activity,” Journal of Hepatol-
ogy, vol. 46, no. 1, pp. 69–76, 2007.
[32] W. Kim, J. H. Yoon, J. R. Kim et al., “Synergistic anti-tumor
eﬃcacy of lovastatin and protein kinase C-beta inhibitor in
hepatocellular carcinoma,” Cancer Chemotherapy and Phar-
macology, vol. 64, no. 3, pp. 497–507, 2009.
[33] J. Gao, Z. Song, Y. Chen et al., “Deregulated expression
of Notch receptors in human hepatocellular carcinoma,”
Digestive and Liver Disease, vol. 40, no. 2, pp. 114–121, 2008.
[34] R. Qi, H. An, Y. Yu et al., “Notch1 signaling inhibits growth
of human hepatocellular carcinoma through induction of cell
cycle arrest and apoptosis,” Cancer Research, vol. 63, no. 23,
pp. 8323–8329, 2003.
[ 3 5 ]L I .N i n g ,L .W e n t w o r t h ,H .C h e n ,a n dS .M .W e b e r ,“ D o w n -
regulation of Notch1 signaling inhibits tumor growth in
human hepatocellular carcinoma,” American Journal of Trans-
lational Research, vol. 1, no. 4, pp. 358–366, 2009.
[36] L. Jakobsson, K. Bentley, and H. Gerhardt, “VEGFRs and
Notch: a dynamic collaboration in vascular patterning,”
Biochemical Society Transactions, vol. 37, no. 6, pp. 1233–1236,
2009.
[37] T. R. Carlson, Y. Yan, X. Wu et al., “Endothelial expression
of constitutively active Notch4 elicits reversible arteriovenous
malformations in adult mice,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 102,
no. 28, pp. 9884–9889, 2005.
[38] P. A. Murphy, M. T. Y. Lam, X. Wu et al., “Endothelial
Notch4 signaling induces hallmarks of brain arteriovenous
malformations in mice,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 105, no. 31, pp.
10901–10906, 2008.
[39] D. Miniati, E. B. Jelin, J. Ng et al., “Constitutively active
endothelial Notch4 causes lung arteriovenous shunts in mice,”
American Journal of Physiology, vol. 298, no. 2, pp. L169–L177,
2010.
[40] X. Z. Wu, G. R. Xie, and D. Chen, “Hypoxia and hepato-
cellular carcinoma: the therapeutic target for hepatocellular
carcinoma,” Journal of Gastroenterology and Hepatology, vol.
22, no. 8, pp. 1178–1182, 2007.
[41] K. Taura, S. De Minicis, E. Seki et al., “Hepatic stellate
cells secrete angiopoietin 1 that induces angiogenesis in liver
ﬁbrosis,” Gastroenterology, vol. 135, no. 5, pp. 1729–1738,
2008.
[42] Y. Xia, R. Chen, Z. Song et al., “Gene expression prowles
during activation of cultured rat hepatic stellate cells by
tumoral hepatocytes and fetal bovine serum,” Journal of
CancerResearchandClinicalOncology,vol.136,no.2,pp.309–
321, 2010.